- Aenova is expanding its microbiology quality control (QC) laboratory at its Latina site by approximately 500 square meters, bringing total lab space to 800 square meters.
- The expansion will create over 20 specialist roles and enable the laboratory to test more than 1,000 batches per year, supporting regulatory compliance and faster process times.
Aenova, a contract development and manufacturing organisation (CDMO), has announced a major expansion of its microbiology QC laboratory at its Latina site. The new facility will enhance sterility testing for biologics, environmental monitoring, bacterial identification, and advanced techniques for bioburden, endotoxins, and viable particle analysis.
The upgraded laboratory will incorporate automation to optimise workflows, improve data reliability, ensure compliance with data integrity principles, and reduce testing cycle times. Construction is expected to finish in the third quarter of 2025, with local regulatory approval anticipated by the fourth quarter.
“With the new microbiology laboratory, Aenova Latina consolidates its role as a strategic partner for pharmaceutical companies, ensuring faster and more effective microbiological testing. This investment allows us to further raise quality standards and reduce time to market for our customers,”
Vittorio Tonus, Head of Quality Operations at Aenova’s Latina site.
The QC lab is part of the broader “Expansion Latina” project, which also includes a cold chain warehouse expected to be operational in early 2026 and a second fill & finish line for sterile injectable and biologics products. These initiatives aim to increase production capacity, strengthen infrastructure, and attract new customers through state-of-the-art equipment and advanced sterile manufacturing capabilities.
